Wolff Wiese Magana’s ImmunityBio IBRX Stock Holding History

Wolff Wiese Magana’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$331K	Buy	37,774 +7,500	+25%	+$56.8K	0.15%	92
2026 Q1	$232K	Buy	30,274 +274	+0.9%	+$1.88K	0.13%	103
2025 Q4	$59.4K	Hold	30,000	–	–	0.03%	191
2025 Q3	$73.8K	Hold	30,000	–	–	0.04%	183
2025 Q2	$79.2K	Buy	30,000 +29,500	+5,900%	+$79.3K	0.05%	168
2025 Q1	$1.5K	Hold	500	–	–	﹤0.01%	784
2024 Q4	$1.28K	Hold	500	–	–	﹤0.01%	778
2024 Q3	$1.86K	Hold	500	–	–	﹤0.01%	750
2024 Q2	$3.16K	Hold	500	–	–	﹤0.01%	486
2024 Q1	$2.69K	Hold	500	–	–	﹤0.01%	472
2023 Q4	$2.51K	Hold	500	–	–	﹤0.01%	451
2023 Q3	$845	Buy	+500	New	+$1K	﹤0.01%	634

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wolff Wiese Magana's IBRX Position: Q2 2026 in Review

Wolff Wiese Magana increased its ImmunityBio (IBRX) stake by 25% in Q2 2026, buying an estimated $56.8K and bringing the position to 37,774 shares worth $331K. The position accounts for 0.15% of the portfolio, ranked #92.

Wolff Wiese Magana first reported a position in IBRX in Q3 2023 and has held it in 12 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Wolff Wiese Magana held 37,774 shares of ImmunityBio worth $331K as of Q2 2026.
Wolff Wiese Magana bought 7,500 ImmunityBio shares in Q2 2026, an estimated $56.8K.
ImmunityBio made up 0.15% of Wolff Wiese Magana's portfolio in Q2 2026, its #92 holding.
Wolff Wiese Magana first reported a position in ImmunityBio in Q3 2023 and has held it in 12 quarters since.
404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Wolff Wiese Magana's 13F filing for Q2 2026, filed 13 Jul 2026.